Background: Chronic breathlessness is a neglected symptom of advanced diseases. Aim: To examine the effect of airflow for chronic breathlessness relief. Design: Exploratory systematic review and meta-analysis. Data sources: Medline, CINAHL, AMED and Cochrane databases were searched for observational studies or randomised controlled trials of airflow as intervention or comparator. Selection against predefined inclusion criteria, quality appraisal and data extraction was conducted by two independent reviewers with access to a third for unresolved differences. 'Before and after' breathlessness measures from airflow arms were analysed. Meta-analysis was carried out where possible. Results: In all, 16 of 78 studies (n = 929) were included: 11 randomised controlled trials of oxygen versus medical air, 4 randomised controlled trials and 1 fan cohort study. Three meta-analyses were possible: (1) Fan at rest in three studies (n = 111) offered significant benefit for breathlessness intensity (0-100 mm visual analogue scale and 0-10 numerical rating scale), mean difference −11.17 (95% confidence intervals (CI) −16.60 to −5.74), p = 0.06 I 2 64%. (2) Medical air via nasal cannulae at rest in two studies (n = 89) improved breathlessness intensity (visual analogue scale), mean difference −12.0 mm, 95% CI −7.4 to −16.6, p < 0.0001 I 2 = 0%. (3) Medical airflow during a constant load exercise test before and after rehabilitation (n = 29) in two studies improved breathlessness intensity (modified Borg scale, 0-10), mean difference −2.9, 95% CI −3.2 to −2.7, p < 0.0001 I 2 = 0%. Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should be considered as an adjunct treatment in the management of breathlessness.
What is already known?
• • Randomised controlled trials and cohort data have demonstrated that airflow delivered from the fan at rest offers significant relief of breathlessness. • • Systematic review and randomised controlled trials of oxygen versus medical air have failed to demonstrate additional benefit from oxygen therapy and suggest that medical air delivery, airflow, is likely to be an active intervention. • • All current evidence available for the effect of airflow for chronic breathlessness relief has not been explored using systematic review methods.
Airflow relieves chronic breathlessness in people with advanced disease: An exploratory systematic review and meta-analyses What this paper adds?
This exploratory systematic review and meta-analyses provide promising data to suggest that • • airflow from the fan at rest improves breathlessness in people with breathlessness due to a variety of causes • • airflow delivered as cylinder medical air at rest improves breathlessness in advanced cancer • • airflow delivered as cylinder medical air during a constant load exercise test improves breathlessness in people with chronic obstructive pulmonary disease and who have completed pulmonary rehabilitation Implications for practice and theory • • Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest in patients who do not require oxygen-enriched air. • • Airflow may benefit exertion-induced breathlessness, but further work is required to investigate the role of the fan with everyday general activity and in relation to exercise. • • Recovery time from exertion-induced breathlessness, self-efficacy and daily activity are key outcomes to explore in future studies of airflow.
Introduction
Breathlessness is a common and often poorly managed symptom in people with advanced diseases. It is associated with reduced quality of life, 1 decreased activities of daily living, 2 unplanned emergency hospital attendance and admission. [3] [4] [5] Breathlessness inflicts devastating and disabling physical, psychological and social burden on normal daily life for the patient, carers and close family members. [6] [7] [8] Chronic breathlessness, that is, breathlessness that persists despite optimal treatment for the underlying pathophysiology and causing such disability, 9 all too often is left for patients to manage themselves despite a developing evidence base for interventions targeted at the breathlessness itself. Growing evidence supports complex non-pharmacological interventions to reduce the impact of the symptom and improve quality of life. [10] [11] [12] Components target peripheral and central afferent sources of breathlessness sensation, such as facial airflow delivered by the batteryoperated handheld fan (fan). [13] [14] [15] [16] [17] Cooling of the facial skin innervated by the second and third branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could modulate the central perception of breathlessness leading to decreased neural respiratory drive, thereby reducing the sensation of breathlessness. [18] [19] [20] [21] [22] A recent multimethods of secondary analysis of qualitative interview data from three studies found that 80/111 (72%) participants experienced benefit when the fan was used in conjunction with other components of a complex intervention. 23 Airflow delivered from the fan may offer a valuable contribution to the self-management of chronic breathlessness 13, 15, 23 and has been identified as a potentially useful strategy in a variety of situations, for example, breathlessness crisis, 24 a component of pulmonary rehabilitation to assist recovery from exercise, or with general everyday activities. 15 Systematic reviews of oxygen in a variety of non-hypoxic patient groups (cancer, chronic heart failure, kyphoscoliosis, chronic obstructive pulmonary disease and interstitial lung disease) have not demonstrated additional benefit from oxygen therapy over medical air delivery. [25] [26] [27] [28] [29] [30] An updated Cochrane review of chronic obstructive pulmonary disease found low-quality evidence for modest relief of breathlessness. 31 The results from a large, adequately powered trial that randomised 239 participants (chronic obstructive pulmonary disease 63%, cancer 16%) to receive at least 15 hours a day of oxygen or medical air delivered via home concentrator for 7 days reaffirm earlier suggestions that medical air used in the placebo arm may not be an inert comparator as previously thought and point to the likelihood of an active intervention. 29, 32 Therefore, the placebo arm of oxygen studies may provide useful preliminary data regarding the role of airflow for the relief of chronic breathlessness. This systematic review aims to identify and evaluate data from studies of airflow, both from studies of the handheld fan and the comparator arm data for breathlessness intensity from oxygen studies, analysed as 'before and after' airflow exposure cohort data.
Aim
To examine the current evidence for the effectiveness of airflow for the relief of chronic breathlessness.
Methods
The systematic review methods employed an exploratory approach in that only the airflow arm of studies were used and the data analysed as cohort 'before and after' treatment.
Study design
The search methods employed are adapted from the Cochrane Handbook of Systematic Reviews 33 and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 34 A review protocol is not preregistered but available from the University of Hull Library (Flavia Swan PhD Thesis).
Inclusion and exclusion criteria
Types of studies Randomised controlled trials, controlled clinical trials (quasi-randomised experimental trials with or without blinding) and observational cohort studies were included.
Types of participants
Adults with chronic breathlessness from any advanced disease aetiology are as shown below: Studies were included, if at least 50% of the study population was classified as advanced, palliative or in the later stages of disease as defined above. These criteria were adapted from the Cochrane review of non-pharmacological interventions for breathlessness. 35 Studies of participants with mild hypo-or normoxaemia, who do not fulfil the criteria for long-term oxygen therapy, 36 were included. Studies of hypoxic participants or patients with any condition not assessed as progressive, refractory to treatment and advanced such as asthma were excluded.
Types of exposure
Airflow: (1) delivered from either a fan (handheld or table) or non-oxygen-enriched compressed air or from a non-invasive ventilatory method (nasal cannula, mask or mouthpiece), but not nasal intermittent positive pressure ventilation and (2) directed at the cheek of the face, nasal mucosae or mouth.
Administration: as (1) a single dose during ambulation or at rest taken as needed (pro re nata), 37 (2) placebo short burst oxygen therapy intermittent use before exercise or after exercise for recovery 36 or (3) continuously over 15 hr a day as placebo long-term oxygen therapy studies or during the night as placebo nocturnal oxygen therapy. 38 Studies where airflow was directly administered to the trachea or at sub-zero temperatures were excluded.
Types of outcome measure
Unidimensional breathlessness outcomes. American Thoracic Society (ATS) domains of dyspnoea measurement 20 including breathlessness severity or intensity rated on unidimensional scales are as shown below: Studies were only included if they reported the breathlessness outcome at baseline and post-treatment measured as either primary or secondary outcomes. If severity or intensity was measured as part of a multidimensional or composite scale, for example, the Chronic Respiratory Questionnaire, that unidimensional measure of breathlessness was not extracted and analysed separately. Breathlessness-related function/quality of life measures were not used as primary breathlessness outcomes in the absence of unidimensional scales.
Other outcomes. Other outcomes as shown below are measured as either primary or secondary outcomes. 
Study selection
Titles and abstracts (and, where unclear, full papers) were screened against the eligibility criteria by two independent reviewers F.S. and A.N., with recourse to M.J. as a third reviewer in case of disagreement.
Data extraction and synthesis
Baseline and post-intervention measures of breathlessness intensity were extracted from the fan studies and from the comparator arm of oxygen studies. Data were analysed as 'before and after' airflow exposure cohort observational data.
Risk of bias
F.S. and A.N. judged the reporting quality and internal validity for each of the included studies. The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a non-randomised study. 39 As there is no tool that is applicable directly to the data extracted from the randomised controlled trials control arms, we assessed instead the quality of the parent randomised controlled trials as a proxy marker for quality data. The randomised controlled trials were assessed with the Cochrane Risk of Bias Tool. 33 See Online Supplementary Table 2 .
Statistical analysis
Results from the meta-analyses were reported for the primary outcome, breathlessness intensity or severity where heterogeneity allowed or where not possible these were described narratively. Numerical rating scales and visual analogue scales were combined by equating one point on a numerical rating scales scale to 10 mm on a visual analogue scales. 40, 41 Data calculations for mean difference and standard deviation used STATA Version 12.1 (Stata Corp LLC Texas 77845-4512, USA). Breathlessness measurements were analysed as continuous outcomes. Data from the placebo arm of crossover randomised controlled trials were treated as single-arm before-after studies. For studies that recorded median values, the mean values were calculated from the extracted study data. 42 The I 2 statistic was used to assess heterogeneity. 43 Where the result indicated significant heterogeneity, a random effects model was chosen, otherwise a fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A sensitivity analysis was attempted for any study identified as including a subgroup not fitting the review criteria of mild hypo or normoxaemia to assess for any significant difference in the breathlessness outcome between the hypoxic and non-hypoxic participants.
Results
A total of 403 records were identified for screening. After removal of duplicates, 78 records were reviewed, of which 14 abstracts were rejected for not meeting inclusion criteria and the remaining 64 full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion criteria and the other 48 studies were excluded (see Figure 1 ; flow chart 34 and Online Supplementary Table 3) .
Overall studies represented 929 participants (age median 61.5, range 33-90 years; 47% men).
Airflow was delivered by fan 13, 14, 16, 17, 44 or as medical air. 29, 32, [45] [46] [47] [48] [49] [50] [51] [52] [53] See Table 1 for study characteristics.
Description of fan studies

Design
Five studies (n = 230) used the fan. Two feasibility randomised controlled trials: (n = 49) 13 and (n = 30), 44 a feasibility cohort study (n = 31), 14 a feasibility longitudinal randomised controlled trial (n = 70) 16 and a phase III crossover randomised controlled trial (n = 50). 17 
Patient characteristics
Four studies recruited a mixed population of people with breathlessness due to a variety of advanced conditions including chronic obstructive pulmonary disease (n = 101), cancer (n = 55), heart failure (n = 23) and other causes (n = 21), 13, 14, 16, 17 and one study recruited advanced cancer only (n = 30). 44 
Intervention and comparator characteristics
Three studies used the fan to face at rest, 14,17,44 two with comparator groups, fan to leg 17 or no fan use and carer support, 44 and the other was a cohort design. 14 One study assessed acceptability of the fan when used with general activity over 6 months compared with an acupressure wristband, 16 and the remaining study assessed the fan when used with exercise advice over 4 weeks. 13 
Breathlessness outcome
Three studies focused on the sensory-perceptual domain of dyspnoea measurement and used breathlessness intensity as the primary outcome 17 or main outcome. 14, 44 These studies selected the visual analogue scale, 17 the numerical rating scale 44 or both visual analogue scale and numerical rating scale. 14 The other two studies assessed symptom impact and the sensory-perceptual domain. These studies selected the numerical rating scale breathlessness intensity 13 and the modified Borg scale of breathlessness severity. 16 
Other outcomes
All of the fan studies reported participant withdrawals. 13, 14, 16, 17, 44 These ranged from 0 to 6 participants. 13, 14, 44 One study reported that there were no adverse events 13 and the other fan studies did not include any adverse event details. 14, 16, 17, 44 Airflow preferences were described in four fan studies 13, 16, 17, 44 and not in one study. 14 In addition, one study quantified the experience of fan use at 2 months. 16 
Description of medical air studies
Design
Eleven randomised controlled trials (n = 699) used oxygen, helium hyperoxia or both gases for the intervention compared with medical air. 29 
Patient characteristics
The 11 studies represent chronic obstructive pulmonary disease (n = 537), cancer (n = 109), other lung diseases (n = 21), cardiac disease (n = 14) and other causes (n = 18). Inclusion criteria required moderate-to-severe chronic obstructive pulmonary disease, 45 or were a mixed population with no specific stipulation of severity. 29, 32 Intervention characteristics 45 15 hours a day over 1 week, 29 or in conjunction with exertion-induced breathlessness during pulmonary rehabilitation 46, 52, 53 or a walking test. [47] [48] [49] The pulmonary rehabilitation programme parameters for airflow delivery were with treadmill exercise 3 times a week for 30 min over 2 months, 53 a cycle ergometer used 3 times a week for 30 min over 6 weeks 46 or 3 times a week for 20 min over 2 months. 52 The 6-min walk test parameters for airflow delivery were (1) three same day 6-min walk tests with 45 min washout, using room air for the basal walk and compressed air for the subsequent walks, 47 (2) five 6-min walk tests performed over three visits (timing not stated) using room air for the practice walk on visit one and cylinder air for the two 6-min walk tests with 60 min washout on visits two and three 48 and (3) three same day 6-min walk tests using cylinder air with 20 min washout between tests at baseline, 6 and 12 weeks, as well as short burst use at home with daily activity during the study period. 49 
Breathlessness outcome
Two studies focused on the sensory-perceptual domain of dyspnoea measurement and recorded breathlessness intensity as a primary outcome with the visual analogue scale and Borg scale 32 or the visual analogue scale only. 51 All of the other studies focused on symptom impact and the sensoryperceptual domain. 29,45-50,52,53 Of these, three studies measured breathlessness intensity as a primary outcome with the numerical rating scale 29 or the Chronic Respiratory Questionnaire dyspnoea domain. 45, 50 The remaining six studies identified the modified Borg scale as one of the main outcomes 47-49,52,53 or a secondary measure. 46 One study in addition selected the Chronic Respiratory Questionnaire. 49 
Other outcomes
Participant withdrawals were reported in all of the studies, 29, 32, [45] [46] [47] [48] [49] [50] [51] 53 apart from one. 52 Five studies reported no withdrawals, 32,46-48,51 and in the other five studies withdrawals ranged from 2 to 21 participants. 45, 53 Adverse events were poorly reported with only two studies including details, 'few' or 'no adverse events'. 29, 46 All of the other studies omitted reporting adverse events. 32, 45, [47] [48] [49] [50] [51] [52] [53] Airflow preferences were only reported in one study. 51 The remaining studies did not report airflow preferences, 29,32,45-48,50,52,53 although one study did quantify side effects 29 and a second study examined preference for cylinder delivery of airflow. 50
Risk of bias
The quality appraisal is summarised in Online Supplementary Table 2 and described below.
Allocation
All of the studies, apart from one, a cohort design, 14 were described as randomised controlled trials. It was possible to verify the randomisation process in eight studies. 
Blinding
Two of the fan studies attempted to blind the participants; 16, 17 a placebo wristband was used as a comparator 16 and participants were not told if the fan to face or fan to leg was the active intervention. 17 There was no blinding in two studies, a cohort and phase II randomised controlled trial, 13,14 and the fifth study stated single blinding that could not be verified from the methods described. 44 All five were judged high risk of bias due to incomplete blinding or limited description. Nine medical air randomised controlled trials were described as double blind. 29,45-52 All were judged low risk of bias, 29, 45, 46, [48] [49] [50] 52 apart from one study that was unclear due to the lack of detail reported. 51 Two randomised controlled trials were single blind; 32,53 one was judged low risk of bias 32 and the other was regarded as unclear risk due to the inadequate description. 53 
Incomplete outcome data
Thirteen studies adequately addressed withdrawals and incomplete outcome data; these were considered low risk of bias. 13, 14, 17, 29, 32, [46] [47] [48] [49] [50] [51] [52] [53] Three studies were uncertain risk: 16, 45 one due to the proportion of attrition 16 and the other two lacked description of how any missing data were statistically managed. 44, 45 Selective outcome reporting
All of the studies reported the prespecified outcomes and were judged as low risk of bias. 13, 14, 16, 17, 29, 32, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Study protocols were available for eight studies. 
Other issues of bias
Twelve studies appeared free from other bias and were judged low risk. 13, 16, 17, 29, [44] [45] [46] 48, [50] [51] [52] [53] Three studies reported insufficient information to adequately assess risk, 32, 47, 49 and one study, a cohort design, was judged high risk. 14
Effect of interventions
The airflow was delivered (1) at rest, 14,17,32,44,51 (2) over days or weeks (either intermittently or as periods of continuous flow) while the participant continued with usual general activities 13, 16, 29, 45, 50 or (3) during specific episodes of exertion-induced breathlessness. [46] [47] [48] [49] 52, 53 At rest
Five studies demonstrated improvement with airflow delivery at rest.
Results from 5 min fan use to the face in three studies were visual analogue scale breathlessness intensity difference from baseline mean −7 mm (confidence interval (CI) −11.5 to −2.5) 17 and mean −12 mm (CI −19.3 to −4.4) 14 and for the numerical rating scale mean change −1.53 (−9.6 to −6.5). 44 Cylinder medical air delivery for 15 min demonstrated improvement visual analogue scale breathlessness intensity mean −11 mm (CI −17.0 to −5.0) 32 and mean −13 mm (CI −20.5 to −6.3). 51 Four studies were subdivided into two groups and included in meta-analyses. 
General activity
Six studies used airflow at home with everyday general activity. A narrative description was used for these due to study diversity. Breathlessness point changes from four cylinder air studies were mixed, 29, 45, 49, 50 with Chronic Respiratory Questionnaire −3.6 after 6 months, 45 3.0 after 12 weeks 49 or 0.9 at 12 weeks, 50 or numerical rating scale −0.7 (am) and −0.5 numerical rating scale (pm) after 7 days. 29 In the two fan studies, a modified Borg score of −0.6 (SD 2.1) was found after 2 months, 16 but there was no numerical rating scale score change after 4 weeks of fan use with exercise advice. 13 
Exertion-induced breathlessness
Six studies examined airflow delivery with exertioninduced breathlessness. Results for mean Borg breathlessness score during a walking test for three studies varied; no change during a 6-min walk test repeated on the same day, 47 or at 12 weeks, 49 and an improvement of −1.5 for a 6-min walk test repeated on three separate visits. 48 Airflow delivered during a constant load exercise test after pulmonary rehabilitation in three studies also demonstrated variable improvement in mean Borg breathlessness scores: −1.8 points 46 and −3 points 52 using a cycle ergometer and −0.5 point from a treadmill test. 53 Two studies were suitable to include in a meta-analysis (see Figure 4) . 46, 52 Medical air. Airflow delivered as cylinder medical air during a constant load exercise test after PR in chronic obstructive pulmonary disease (n = 29) significantly improved breathlessness Borg score mean difference −2.9 (CI −3.2 to −2.7), p < 0.0001. No evidence of heterogeneity was observed, χ 2 p-value = 0.7 (I² = 0%) (Figure 4 ).
Discussion
These exploratory data support that facial and nasal airflow delivery at rest offers relief of breathlessness intensity consistent with a moderate clinically important difference 54, 55 and during exertion. 46, 52 All participants in the cylinder medical air delivery at rest studies had advanced cancer, but nearly half of those in the fan 'at rest' studies had other conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.
In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with chronic breathlessness, 9 over 80% patients reported some or substantial benefit. 23 However, the data presented here varied with regard to relief of breathlessness intensity when facial or nasal airflow delivery was used with everyday general activity or with exertion-induced breathlessness. This may reflect the use of outcome measures that do not reliably capture change in breathlessness intensity in the context of exertion. Studies that used a 6-min walk test [47] [48] [49] highlight the problem of a self-paced test that allows patients to control their walking speed and thus limit the maximal level of exertion-induced breathlessness experienced. In contrast, studies that used an externally paced test, such as the cycle ergometer, identified relief of breathlessness intensity. 46, 52 The relationship between exercise and breathlessness intensity is complex, and measuring one without taking the other into account may miss relevant improvement. Scores are likely to remain static after the introduction of an intervention as patients are able to exert themselves to the same level of breathlessness without noticing an increase in their exercise tolerance, 56 or indeed the outcome may be of little value to the patient. 23 A previous study of recovery time after an incremental shuttle walk test in people with thoracic cancer (n = 57) reported a rapid reduction in breathlessness intensity with a return to baseline time of median 4 min (interquartile range 2-5 min). 57 The analysis of 133 patient interviews found that a faster recovery time was a key patient-reported benefit of airflow delivered from the fan, irrespective of breathlessness intensity. 23 Even though recovery time may only be a matter of minutes, interventions which shorten this further are clearly welcomed and give the patient a sense of self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover quickly and predictably from bouts of exertion is likely to encourage further activity and prevent the deconditioning cycle.
The fan therefore seems suitable as a patient-delivered intervention to target the recovery time from exertioninduced breathlessness. Preliminary magnetoencephalography imaging data suggest airflow delivery during recovery from exercise may modulate central perception of breathlessness by modifying sensory attention. 58 Cooling of the facial skin innervated by the second and third branches of the trigeminal nerve and/or stimulation of nasal mucosa and upper airway 'flow' receptors is reported to improve breathlessness intensity and exercise tolerance 18, 19, 59, 60 and could 'fool' the brain into thinking that the respiratory status is adequate. 22 Unpleasant respiratory sensations associated with exercise are known to adversely influence adherence to an exercise regime. 61 Therefore, use of airflow as part of pulmonary rehabilitation may help the problems of low patient attendance and poor maintenance of long-term outcomes. [62] [63] [64] [65] Facial airflow from fan use during a cycle ergometer test in chronic obstructive pulmonary disease patients resulted in significant breathlessness reduction and a longer total exercise time. 66 Likewise, the meta-analysis result from this systematic review suggests significant relief of breathlessness when airflow is delivered during exercise. These data highlight the potential value of using airflow delivery with pulmonary rehabilitation or homebased exercise programmes. In addition, intervention preference and adverse event data support the role of the fan in this context as a portable device that is unlikely to harm and therefore appropriate for the majority of patients to try.
Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday general activity and at rest were not captured in the review data. The lack of signal from the results may in part reflect the complexity and the nuances of when, where and how this intervention is used by patients. 23 Current breathlessness management is modelled on a complex intervention, of which the fan is identified as a valuable therapeutic component alongside other interventions and strategies that are tailored to the patient's breathlessness needs. 11, 67 Limitation of methods Data were analysed as cohort 'before and after' design, and no adjustments were made to control for confounding bias. The pre-post comparison increases the potential risk of bias, and it is possible that results may be influenced by the timing of 'before and after' measures. For example, studies of longer duration (up to 6 months) may not be representative of the immediate benefits of airflow, but rather reflect more complex use and mechanism of any observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of bias was assessed using a tool designed for randomised controlled trials; therefore, it is possible that this assessment may not capture potential sources of bias associated with the observational methods used in this systematic review.
Overall, the qualitative synthesis represents findings from 929 participants, the largest to date; however, the meta-analyses pertain to a small number of participants and only provide a preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve few studies; therefore, heterogeneity is difficult to estimate and the accuracy of the I 2 value is less certain. 68 The number of studies that fulfilled the review criteria was restricted by the need for baseline breathlessness measures. Some of the included studies 32, 51 did not report repeated measurements in a format suitable for metaanalysis necessitating statistical assumptions. 42 
Implications for practice and further research
Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in those who do not require oxygen-enriched air. Clinicians should consider airflow an important intervention to use as part of a breathlessness management programme in breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in those with chronic obstructive pulmonary disease may provide a useful intervention during pulmonary rehabilitation where breathlessness is a reason for poor adherence.
The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time from exertion-induced breathlessness is an important patient-reported outcome, and further work is needed to explore the role of airflow in recovery, self-efficacy and increased daily activity as part of complex breathlessness intervention programmes including rehabilitation.
Conclusion
These data support facial or nasal airflow for clinically meaningful relief of breathlessness at rest. This systematic review pulls together the growing evidence to support airflow as an effective self-management option for people with chronic breathlessness and identifies airflow as an intervention for future study.
Data management and sharing
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